ABCC5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2800423	0.66	2/20
SCHEMBL2806791	0.66	2/20
SCHEMBL2799404	0.64	2/20
SCHEMBL931	0.58	2/20
SCHEMBL2802379	0.57	2/20
SCHEMBL5901713	0.48	2/20
SCHEMBL6619696	0.47	2/20
SCHEMBL5901246	0.47	2/20
SCHEMBL5902232	0.47	2/20
SCHEMBL5330304	0.46	2/20
Hydrochloric Acid (SCHEMBL5355292)	0.45	2/20
Hydrochloric Acid (SCHEMBL5365443)	0.45	2/20
SCHEMBL6332572	0.44	2/20
SCHEMBL6339983	0.44	2/20
SCHEMBL5901814	0.43	2/20
SCHEMBL6334387	0.43	2/20
SCHEMBL6332138	0.42	2/20
Sildenafil (SCHEMBL1895)	1.00	1/20
Dipyridamole (SCHEMBL16119)	1.00	1/20
Verlukast (SCHEMBL37246)	1.00	1/20

Clinical trials — most relevant to ABCC5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients	PHASE4	COMPLETED
Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care	PHASE4	COMPLETED
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	PHASE3	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer	PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas	PHASE2	COMPLETED
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants	PHASE1	ACTIVE_NOT_RECRUITING
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	PHASE1	COMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control	nan	COMPLETED
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia	nan	ACTIVE_NOT_RECRUITING
Placental Transfer of Tenofovir	nan	COMPLETED
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia	nan	COMPLETED
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population	nan	RECRUITING
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Pharmacogenomics of New Antiretrovirals	nan	COMPLETED
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District	nan	UNKNOWN
Collection of Tissue Samples for Study of Multidrug Resistance	nan	COMPLETED
A Prospective Study on Effect of Systemic Adjuvant Therapy on Cognitive and Brain Function of Breast Cancer Patients	nan	UNKNOWN
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Effect of Pharmacogenetics on Imatinib Plasma Level and Response	nan	COMPLETED
Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia	nan	UNKNOWN
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871	nan	COMPLETED
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ABCC5 binder may also engage these)

Protein	Name	Similarity
Q9QYM0	—	1.000	Q9QYM0 →
Q9R1X5	—	1.000	Q9R1X5 →
Q96J66	—	0.998	Q96J66 →
ABCC8	ATP-binding cassette sub-family C member 8	0.997	landscape →
Q09429	—	0.997	Q09429 →
Q09YH0	—	0.996	Q09YH0 →
Q7JII8	—	0.996	Q7JII8 →
Q9TUQ2	—	0.996	Q9TUQ2 →
Q09427	—	0.996	Q09427 →
Q63120	—	0.996	Q63120 →
Q2QLH0	—	0.995	Q2QLH0 →
P26361	—	0.995	P26361 →
Q63563	—	0.995	Q63563 →
Q6Y306	—	0.994	Q6Y306 →
Q07E16	—	0.994	Q07E16 →
Q9U2G5	—	0.994	Q9U2G5 →
Q80WJ6	—	0.994	Q80WJ6 →
P91660	—	0.994	P91660 →
Q9M1C7	—	0.994	Q9M1C7 →
Q9C8G9	—	0.994	Q9C8G9 →
Q00554	—	0.994	Q00554 →
Q1LX78	—	0.994	Q1LX78 →
Q2QLB4	—	0.993	Q2QLB4 →
P39109	—	0.993	P39109 →
Q96J65	—	0.993	Q96J65 →
Q8VI47	—	0.993	Q8VI47 →
Q00555	—	0.993	Q00555 →
P82451	—	0.993	P82451 →
Q09YK5	—	0.993	Q09YK5 →
Q10185	—	0.993	Q10185 →